Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Yongxing Du

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3334-6561; OpenAlex author ID A5002743640, A5122966634. Sources: OpenAlex.

Their work

Papers
27 (first author 9, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
45
Papers, trials and grants by year

2016: 3 papers · 2017: 2 papers · 2018: none · 2019: none · 2020: 1 paper · 2021: 4 papers · 2022: 5 papers · 2023: 4 papers · 2024: none · 2025: 4 papers · 2026: 4 papers

Papers 27

  1. Metabolic signatures of lipid dysregulation and inflammation characterize pancreatic cancer risk in type 2 diabetes mellitus and improve risk stratification: a… Last author DOI 10.1016/j.diabres.2026.113230↗
  2. Elevated circulating glycine levels are associated with reduced pancreatic cancer risk: A prospective cohort study based on the UK biobank. Last author DOI 10.1016/j.pan.2025.12.015↗
  3. Association between female reproductive factors and new-onset pancreatic cancer risk: a prospective cohort study. Co-author DOI 10.1097/cej.0000000000000987↗
  4. [Expression of Concern] c‑Fos/ERK promotes the progression from pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/or.2026.9092↗
  5. Delayed gastric emptying risk stratification in patients with pancreatic ductal adenocarcinoma after pancreatoduodenectomy: An international validation cohort … First author DOI 10.1002/ueg2.12688↗
  6. Tumor-derived miR-203a-3p potentiates muscle wasting by inducing muscle ferroptosis in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2025.217523↗
  7. Prevalence, clinicopathological features, and prognosis of diabetes in pancreatic cancer: A single-center retrospective cohort study of 1620 patients. Co-author DOI 10.1016/j.pan.2025.11.004↗
  8. SDC-1 deficiency enhances the pancreatic cancer response to PD-1 antibody by reprogramming tumor microenvironment Co-author DOI 10.21203/rs.3.rs-6802997/v1↗
  9. ITGA3 acts as a purity-independent biomarker of both immunotherapy and chemotherapy resistance in pancreatic cancer: bioinformatics and experimental analysis. First author DOI 10.1007/s10142-023-01122-z↗
  10. Expression, prognostic value and mechanism of SP100 family in pancreatic adenocarcinoma. First author DOI 10.18632/aging.204811↗
  11. Subcellular localization of nucleolar protein 14 and its proliferative function mediated by miR-17-5p and E2F4 in pancreatic cancer. Co-author DOI 10.18632/aging.204915↗
  12. Clinicopathological Features, Immune Infiltration Landscape and Involved Signaling Pathways of the desmogleins family in Pancreatic Adenocarcinoma First author DOI 10.21203/rs.3.rs-2971625/v1↗
  13. Dynamic Interplay between Structural Variations and 3D Genome Organization in Pancreatic Cancer. Co-author DOI 10.1002/advs.202200818↗
  14. Expression, Prognostic Value, and Functional Mechanism of the KDM5 Family in Pancreatic Cancer. First author DOI 10.3389/fcell.2022.887385↗
  15. Prognostic value, immune signature and molecular mechanisms of the APOBEC family members APOBEC1, APOBEC3A, APOBEC3G and APOBEC3H in pancreatic adenocarcinoma. First author DOI 10.3389/fmolb.2022.1036287↗
  16. Prognostic value, immune signature and molecular mechanisms of the SUMO family in pancreatic adenocarcinoma. First author DOI 10.3389/fmolb.2022.1096679↗
  17. Prognostic Value, Immune Signature, and Molecular Mechanisms of the PHLDA Family in Pancreatic Adenocarcinoma. First author DOI 10.3390/ijms231810316↗
  18. Tumor microenvironment and metabolic remodeling in gemcitabine-based chemoresistance of pancreatic cancer. First author DOI 10.1016/j.canlet.2021.08.029↗
  19. Intraoperative radiotherapy vs concurrent chemoradiotherapy in the treatment of patients with locally advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2021.04.007↗
  20. Preoperative Alkaline Phosphatase-to-Cholesterol Ratio as a Predictor of Overall Survival in Pancreatic Ductal Adenocarcinoma Patients Undergoing Radical Pancr… Co-author DOI 10.12659/msm.931868↗
  21. Combination of preoperative fibrinogen and D-dimer as a prognostic indicator in pancreatic ductal adenocarcinoma patients undergoing R0 resection. Co-author DOI 10.4240/wjgs.v13.i3.279↗
  22. Prognostic value of the preoperative fibrinogen-to-albumin ratio in pancreatic ductal adenocarcinoma patients undergoing R0 resection. Co-author DOI 10.3748/wjg.v26.i46.7382↗
  23. Pancreatic Cancer Progression Relies upon Mutant p53-Induced Oncogenic Signaling Mediated by NOP14. Co-author DOI 10.1158/0008-5472.can-16-2339↗
  24. Molecular Subtyping of Pancreatic Cancer: Translating Genomics and Transcriptomics into the Clinic. Co-author DOI 10.7150/jca.17622↗
  25. Advances in understanding the molecular mechanism of pancreatic cancer metastasis. Co-author DOI 10.1016/s1499-3872(15)60033-9↗
  26. Activator protein 1 promotes gemcitabine-induced apoptosis in pancreatic cancer by upregulating its downstream target Bim. Co-author DOI 10.3892/ol.2016.5294↗
  27. c-Fos/ERK promotes the progression from pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/or.2016.5169↗

Closest collaborators

The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zongting Gu · 11 shared papers, 2021–2025 · strength 2.16
  2. Yunjie Duan · 8 shared papers, 2022–2025 · strength 1.74
  3. Xiaohao Zheng · 8 shared papers, 2021–2025 · strength 1.69
  4. Xu Che · 5 shared papers, 2023–2026 · strength 1.45
  5. Chengfeng Wang · 6 shared papers, 2021–2026 · strength 1.39
  6. Shuai Xiang · 4 shared papers, 2025–2026 · strength 1.26
  7. Yunlong Li · 4 shared papers, 2025–2026 · strength 1.26
  8. Chengfeng Wang · 6 shared papers, 2020–2023 · strength 1.00
  9. Chengfeng Wang · 3 shared papers, 2022–2025 · strength 0.74
  10. Lei You · 6 shared papers, 2016–2026 · strength 0.68
  11. Yupei Zhao · 5 shared papers, 2016–2026 · strength 0.61
  12. Hu Ren · 4 shared papers, 2020–2021 · strength 0.58
  13. Lipeng Zhang · 3 shared papers, 2020–2021 · strength 0.42
  14. Shanglong Liu · 1 shared paper, 2026 · strength 0.32
  15. Jianwei Zhang · 1 shared paper, 2025 · strength 0.30
  16. Xiaoxia Ren · 4 shared papers, 2016–2017 · strength 0.27
  17. Mingyang Liu · 1 shared paper, 2023 · strength 0.26
  18. Guotong Qiu · 2 shared papers, 2021 · strength 0.26
  19. Shuisheng Zhang · 1 shared paper, 2025 · strength 0.26
  20. Hanteng Yang · 1 shared paper, 2025 · strength 0.26
  21. Shunda Wang · 1 shared paper, 2025 · strength 0.26
  22. Chengyun Li · 1 shared paper, 2025 · strength 0.26
  23. Yumeng Hu · 1 shared paper, 2025 · strength 0.22
  24. Shaobo Zhang · 1 shared paper, 2025 · strength 0.22
  25. Zhihua Liu · 1 shared paper, 2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.